Annexin Pharmaceuticals AB develops a Annexin A5 for treatment of cardiovascular diseases.The project is at a late preclinical stage and several risk factors have been eliminated. The focus is to obtain a proof of concept for patients with peripheral arterial occlusive disease within three years. If we succeed, Annexin A5 will be a breakthrough in cardiovascular disease and potentially in other chronic inflammatory conditions.